Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Next Previous
X
Search
Trial Profile

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone; Dexamethasone; Methylprednisolone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms CANDOR
  • Sponsors Amgen; Ono Pharmaceutical

    • Most Recent Events

    • 12 Dec 2023 Results post hoc analysis used a planned interim readout of frailty subgroup of CANDOR study, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 01 Sep 2022 Results of subgroup analysis assessing outcomes baes on cytogenetic risk published in the British Journal of Haematology
    • 29 Jun 2022 This trial has been completed in Austria according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top